Description: Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Home Page: www.ampiopharma.com
373 Inverness Parkway
Englewood,
CO
80112
United States
Phone:
720 437 6500
Officers
| Name | Title |
|---|---|
| Mr. Michael A. Martino | CEO & Director |
| Dr. David Bar-Or M.D. | Founder & Chairman of Scientific Advisory Board |
| Mr. Daniel G. Stokely CPA, CPA | CFO, Corp. Sec. & Treasurer |
| Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. | Chief Medical Officer |
| Lane Hapke | VP of Manufacturing Operations |
| April Ramirez | Clinical Trial Mang. |
| Laura Goldberg | VP of Quality and Regulatory Operations |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4707 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |